- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 7 - Immunotherapy: Where Is It At? Where Is It Headed?
Panelists Daniel J. George, MD, and Jeffrey Weber, MD, PhD, believe that while immunotherapy is still relatively new, this therapy option will play a promising role in the future for the treatment of cancer.
Immunotherapy is the most exciting area in cancer research right now, declares Dr George.
Dr George credits the IMPACT trial as a pivotal trial that led to the approval of Provenge, the first cellular immunotherapy approved by the FDA for the treatment of metastatic prostate cancer, and elaborates on the PSA quartile trial. He explains how the benefits of trials, in terms of overall survival and long-term disease-free survival with checkpoint inhibitors, help immunotherapy gain credibility for the treatment of cancer.
Dr Weber continues by highlighting current key trials featured during the ASCO 2013 meetings, which include trials for PD-1 antibodies, ipilimumab, and new combinations of ipilimumab with granulocyte-macrophage colony-stimulating factors (GM-CSFs).
George hopes that the results of key trials will help change the population of patients who can be treated with immunotherapy, as well as help providers treat patients in a more precise manner.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Specialty Drug Users to Gain Relief Under Medicare Reforms
May 16th 2025A new analysis looked at estimated out-of-pocket costs for etanercept, ustekinumab, and ibrutinib, specialty drugs that often represent a significant cost burden for Medicare Part D beneficiaries and which were selected for 2026 drug price negotiation under the Inflation Reduction Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Navigation and Clinician Payment Investments Enhance Colorectal Cancer Screening Benefits
May 15th 2025Investing in patient navigation and clinician incentives ensures colorectal cancer screening completion, improves early detection, reduces disparities, achieves cost savings, and advances population health for all stakeholders.
Read More
